In conclusion, our study demonstrates that IL-9 promotes proliferation and metastasis in pancreatic cancer cells and that this effect may occur via regulation of the miR-200a/β-catenin axis, suggesting that both IL-9 and miR-200a could be used as potential biomarkers in the treatment of pancreatic cancer. The gene discussed is IL9; the disease is familial pancreatic carcinoma.